Skip to main content
SpringerLink
Log in

MicroRNAs in Cancer Drug Resistance and Drug Sensitivity

  • Chapter
  • First Online:
MicroRNAs: Key Regulators of Oncogenesis

  • 1297 Accesses

Abstract

MicroRNAs (miRNAs) are important regulators of distinct biological processes and are tightly related with several diseases, including cancer. In the last years, miRNAs have been shown to play an important role in drug resistance/sensitivity to anticancer drugs. This chapter first addresses the phenomenon of drug resistance in cancer cells. It then describes the role of miRNAs in drug resistance or drug sensitivity, including a review of the role of miRNAs and their validated targets in cancer drug resistance. Furthermore, it focuses on miRNAs that target cellular proteins related to drug resistance such as p53 or proteins involved in cellular processes such as apoptosis, autophagy, DNA damage response, epithelial to mesenchymal transition and cancer stem cell phenotype, drug efflux or drug metabolism. In addition, the non-genetic acquisition of drug resistance through the transfer of miRNAs from drug resistant to drug sensitive cells via microvesicles or exosomes is also discussed. Finally, the known miRNA polymorphisms associated with drug resistance are addressed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Acunzo M, Visone R, Romano G, Veronese A, Lovat F, Palmieri D et al (2012) miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene 31(5):634–642

    CAS  PubMed Central  PubMed  Google Scholar 

  • Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A et al (2009) miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 15(16):5060–5072

    CAS  PubMed  Google Scholar 

  • Akao Y, Noguchi S, Iio A, Kojima K, Takagi T, Naoe T (2011) Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett 300(2):197–204

    CAS  PubMed  Google Scholar 

  • Akhdar H, Legendre C, Aninat C, More F (2012) Anticancer drug metabolism: chemotherapy resistance and new therapeutic approaches. In: Paxton DJ (ed) Topics on drug metabolism. InTech, Rijeka, pp 137–171

    Google Scholar 

  • Bai H, Xu R, Cao Z, Wei D, Wang C (2011) Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett 585(2):402–408

    CAS  PubMed  Google Scholar 

  • Bai H, Cao Z, Deng C, Zhou L, Wang C (2012) miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C by inducing apoptosis. J Cancer Res Clin Oncol 138(4):595–602

    CAS  PubMed  Google Scholar 

  • Bai Y, Liao H, Liu T, Zeng X, Xiao F, Luo L et al (2013) MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-a-go-go (EAG1). Eur J Cancer 49(3):710–724

    CAS  PubMed  Google Scholar 

  • Bao L, Hazari S, Mehra S, Kaushal D, Moroz K, Dash S (2012) Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol 180(6):2490–2503

    CAS  PubMed  Google Scholar 

  • Bergamaschi A, Katzenellenbogen BS (2012) Tamoxifen downregulation of miR-451 increases 14-3-3zeta and promotes breast cancer cell survival and endocrine resistance. Oncogene 31(1):39–47

    CAS  PubMed Central  PubMed  Google Scholar 

  • Bhatnagar N, Li X, Padi SK, Zhang Q, Tang MS, Guo B (2010) Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 1:e105

    CAS  PubMed Central  PubMed  Google Scholar 

  • Bhutia YD, Hung SW, Krentz M, Patel D, Lovin D, Manoharan R et al (2013) Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein. PloS One 8(1):e53436

    CAS  PubMed Central  PubMed  Google Scholar 

  • Bian HB, Pan X, Yang JS, Wang ZX, De W (2011) Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res 30:20

    CAS  PubMed  Google Scholar 

  • Bisso A, Faleschini M, Zampa F, Capaci V, De Santa J, Santarpia L et al (2013) Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle 12(11):1679–1687

    CAS  PubMed  Google Scholar 

  • Bitarte N, Bandres E, Boni V, Zarate R, Rodriguez J, Gonzalez-Huarriz M et al (2011) MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells 29(11):1661–1671

    CAS  PubMed  Google Scholar 

  • Blower PE, Verducci JS, Lin SL, Zhou J, Chung JH, Dai ZY et al (2007) MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 6(5):1483–1491

    CAS  PubMed  Google Scholar 

  • Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z et al (2008) MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 7(1):1–9

    CAS  PubMed  Google Scholar 

  • Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K et al (2013) MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun 4:1393

    PubMed Central  PubMed  Google Scholar 

  • Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE et al (2007) p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 17(15):1298–1307

    CAS  PubMed  Google Scholar 

  • Boni V, Bitarte N, Cristobal I, Zarate R, Rodriguez J, Maiello E et al (2010) miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol Cancer Ther 9(8):2265–2275

    CAS  PubMed  Google Scholar 

  • Boni V, Zarate R, Villa JC, Bandres E, Gomez MA, Maiello E et al (2011) Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. Pharmacogenomics J 11(6):429–436

    CAS  PubMed  Google Scholar 

  • Borralho PM, Kren BT, Castro RE, da Silva IB, Steer CJ, Rodrigues CM (2009) MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J 276(22):6689–6700

    CAS  PubMed  Google Scholar 

  • Borst P (2012) Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol 2(5):120066

    PubMed Central  PubMed  Google Scholar 

  • Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E (2009) Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem 284(39):26533–26546

    CAS  PubMed  Google Scholar 

  • Bourguignon LY, Wong G, Earle C, Chen L (2012) Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem 287(39):32800–32824

    CAS  PubMed  Google Scholar 

  • Boyd MR, Pauli KD (1995) Some practical considerations and applications of the National-Cancer-Institute in-vitro anticancer drug discovery screen. Drug Dev Res 34(2):91–109

    CAS  Google Scholar 

  • Boyerinas B, Park SM, Murmann AE, Gwin K, Montag AG, Zillhardt M et al (2012) Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer/Journal International du Cancer 130(8):1787–1797

    CAS  Google Scholar 

  • Broxterman HJ, Gotink KJ, Verheul HM (2009) Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Update 12(4–5):114–126

    CAS  Google Scholar 

  • Brunner S, Herndler-Brandstetter D, Arnold CR, Wiegers GJ, Villunger A, Hackl M et al (2012) Upregulation of miR-24 is associated with a decreased DNA damage response upon etoposide treatment in highly differentiated CD8(+) T cells sensitizing them to apoptotic cell death. Aging Cell 11(4):579–587

    CAS  PubMed Central  PubMed  Google Scholar 

  • Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L (2010) Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int 78(9):838–848

    CAS  PubMed  Google Scholar 

  • Cannell IG, Kong YW, Johnston SJ, Chen ML, Collins HM, Dobbyn HC et al (2010) p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication. Proc Natl Acad Sci U S A 107(12):5375–5380

    CAS  PubMed Central  PubMed  Google Scholar 

  • Cao M, Seike M, Soeno C, Mizutani H, Kitamura K, Minegishi Y et al (2012) MiR-23a regulates TGF-beta-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. Int J Oncol 41(3):869–875

    CAS  PubMed  Google Scholar 

  • Catuogno S, Cerchia L, Romano G, Pognonec P, Condorelli G, de Franciscis V (2013) miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene 32(3):341–351

    CAS  PubMed  Google Scholar 

  • Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M et al (2010) Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 8(9):1207–1216

    CAS  PubMed  Google Scholar 

  • Chai H, Liu M, Tian R, Li X, Tang H (2011) miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim Biophys Sin 43(3):217–225

    CAS  PubMed  Google Scholar 

  • Chang CJ, Hsu CC, Chang CH, Tsai LL, Chang YC, Lu SW et al (2011) Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer. Oncol Rep 26(4):1003–1010

    CAS  PubMed  Google Scholar 

  • Chen F, Zhu HH, Zhou LF, Wu SS, Wang J, Chen Z (2010a) Inhibition of c-FLIP expression by miR-512-3p contributes to taxol-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep 23(5):1457–1462

    CAS  PubMed  Google Scholar 

  • Chen Y, Zuo J, Liu Y, Gao H, Liu W (2010b) Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cells. Chin J Cancer 29(12):1006–1011

    CAS  PubMed  Google Scholar 

  • Chen F, Chen C, Yang S, Gong W, Wang Y, Cianflone K et al (2012a) Let-7b inhibits human cancer phenotype by targeting cytochrome P450 epoxygenase 2J2. PloS One 7(6):e39197

    CAS  PubMed Central  PubMed  Google Scholar 

  • Chen J, Tian W, Cai H, He H, Deng Y (2012b) Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol 29(4):2527–2534

    CAS  PubMed  Google Scholar 

  • Chen PS, Su JL, Hung MC (2012c) Dysregulation of microRNAs in cancer. J Biomed Sci 19:90

    CAS  PubMed  Google Scholar 

  • Chen Y, Tsai YH, Fang Y, Tseng SH (2012d) Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells. J Pediatr Surg 47(10):1797–1805

    PubMed  Google Scholar 

  • Chen J, Chen Y, Chen Z (2013a) MiR-125a/b regulates the activation of cancer stem cells in paclitaxel-resistant colon cancer. Cancer Invest 31(1):17–23

    CAS  PubMed  Google Scholar 

  • Chen L, Tang Y, Wang J, Yan Z, Xu R (2013b) miR-421 induces cell proliferation and apoptosis resistance in human nasopharyngeal carcinoma via downregulation of FOXO4. Biochem Biophys Res Commun 435(4):745–750

    CAS  PubMed  Google Scholar 

  • Cheng W, Liu T, Wan X, Gao Y, Wang H (2012) MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J 279(11):2047–2059

    CAS  PubMed  Google Scholar 

  • Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I et al (2008) A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res 68(20):8535–8540

    CAS  PubMed Central  PubMed  Google Scholar 

  • Choi YM, An S, Lee EM, Kim K, Choi SJ, Kim JS et al (2012) CYP1A1 is a target of miR-892a-mediated post-transcriptional repression. Int J Oncol 41(1):331–336

    CAS  PubMed  Google Scholar 

  • Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, Jones FE (2010a) Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis 31(12):2049–2057

    CAS  PubMed  Google Scholar 

  • Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD et al (2010b) Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer 9:317

    CAS  PubMed Central  PubMed  Google Scholar 

  • Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS et al (2012) Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther 11(12):2556–2565

    CAS  PubMed Central  PubMed  Google Scholar 

  • Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK (2009) MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 8(5):1055–1066

    CAS  PubMed  Google Scholar 

  • Dai B, Meng J, Peyton M, Girard L, Bornmann WG, Ji L et al (2011) STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res 71(10):3658–3668

    CAS  PubMed Central  PubMed  Google Scholar 

  • Dalgard CL, Gonzalez M, deNiro JE, O’Brien JM (2009) Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells. Invest Ophthalmol Vis Sci 50(10):4542–4551

    PubMed  Google Scholar 

  • Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M et al (2007) Non-transcriptional control of DNA replication by c-Myc. Nature 448(7152):445–451

    CAS  PubMed  Google Scholar 

  • Dong J, Zhao YP, Zhou L, Zhang TP, Chen G (2011) Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells. Arch Med Res 42(1):8–14

    CAS  PubMed  Google Scholar 

  • Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F et al (2012) MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 19(6):1038–1048

    CAS  PubMed  Google Scholar 

  • Dore LC, Amigo JD, Dos Santos CO, Zhang Z, Gai X, Tobias JW et al (2008) A GATA-1-regulated microRNA locus essential for erythropoiesis. Proc Natl Acad Sci U S A 105(9):3333–3338

    CAS  PubMed Central  PubMed  Google Scholar 

  • Douville J, Beaulieu R, Balicki D (2009) ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev 18(1):17–25

    CAS  PubMed  Google Scholar 

  • Du L, Subauste MC, DeSevo C, Zhao Z, Baker M, Borkowski R et al (2012) miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PloS One 7(6):e39167

    CAS  PubMed Central  PubMed  Google Scholar 

  • Elhassan MO, Christie J, Duxbury MS (2012) Homo sapiens systemic RNA interference-defective-1 transmembrane family member 1 (SIDT1) protein mediates contact-dependent small RNA transfer and microRNA-21-driven chemoresistance. J Biol Chem 287(8):5267–5277

    CAS  PubMed  Google Scholar 

  • Feng DD, Zhang H, Zhang P, Zheng YS, Zhang XJ, Han BW et al (2011) Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med 15(10):2164–2175

    CAS  PubMed  Google Scholar 

  • Feng B, Wang R, Chen LB (2012a) MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett 317(2):184–191

    CAS  PubMed  Google Scholar 

  • Feng B, Wang R, Song HZ, Chen LB (2012b) MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. Cancer 118(13):3365–3376

    CAS  PubMed  Google Scholar 

  • Ferracin M, Zagatti B, Rizzotto L, Cavazzini F, Veronese A, Ciccone M et al (2010) MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol Cancer 9:123

    PubMed Central  PubMed  Google Scholar 

  • Flamant S, Ritchie W, Guilhot J, Holst J, Bonnet ML, Chomel JC et al (2010) Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica 95(8):1325–1333

    CAS  PubMed  Google Scholar 

  • Fletcher JI, Haber M, Henderson MJ, Norris MD (2010) ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 10(2):147–156

    CAS  PubMed  Google Scholar 

  • Fojo T (2007) Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Update 10(1–2):59–67

    CAS  Google Scholar 

  • Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S et al (2009) MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 69(14):5761–5767

    CAS  PubMed  Google Scholar 

  • Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL et al (2010) MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 70(12):5184–5193

    CAS  PubMed  Google Scholar 

  • Fornari F, Milazzo M, Chieco P, Negrini M, Marasco E, Capranico G et al (2012) In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. J Pathol 227(3):275–285

    CAS  PubMed  Google Scholar 

  • Frankel LB, Wen J, Lees M, Hoyer-Hansen M, Farkas T, Krogh A et al (2011) microRNA-101 is a potent inhibitor of autophagy. EMBO J 30(22):4628–4641

    CAS  PubMed  Google Scholar 

  • Fu X, Tian J, Zhang L, Chen Y, Hao Q (2012) Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett 586(9):1279–1286

    CAS  PubMed  Google Scholar 

  • Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y et al (2008) Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 377(1):114–119

    CAS  PubMed  Google Scholar 

  • Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y, Kitamoto A et al (2010) MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 285(25):19076–19084

    CAS  PubMed  Google Scholar 

  • Gal H, Pandi G, Kanner AA, Ram Z, Lithwick-Yanai G, Amariglio N et al (2008) MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. Biochem Biophys Res Commun 376(1):86–90

    CAS  PubMed  Google Scholar 

  • Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A et al (2010) miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 70(5):1793–1803

    CAS  PubMed  Google Scholar 

  • Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C et al (2008) MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 27(27):3845–3855

    CAS  PubMed  Google Scholar 

  • Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A et al (2009) miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16(6):498–509

    CAS  PubMed Central  PubMed  Google Scholar 

  • Garofalo M, Quintavalle C, Romano G, Croce CM, Condorelli G (2012a) miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med 12(1):27–33

    CAS  PubMed Central  PubMed  Google Scholar 

  • Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A et al (2012b) EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 18(1):74–82

    CAS  Google Scholar 

  • Garraway LA, Janne PA (2012) Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2(3):214–226

    CAS  PubMed  Google Scholar 

  • Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen CF et al (2007) Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 67(6):2456–2468

    CAS  PubMed  Google Scholar 

  • Gerlinger M, Swanton C (2010) How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 103(8):1139–1143

    CAS  PubMed Central  PubMed  Google Scholar 

  • Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New Engl J Med 366(10):883–892

    CAS  PubMed  Google Scholar 

  • Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Vasile E et al (2010) MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 70(11):4528–4538

    CAS  PubMed  Google Scholar 

  • Gmeiner WH, Reinhold WC, Pommier Y (2010) Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. Mol Cancer Ther 9(12):3105–3114

    CAS  PubMed Central  PubMed  Google Scholar 

  • Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J et al (2011) Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 286(21):19127–19137

    CAS  PubMed  Google Scholar 

  • Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2(1):48–58

    CAS  PubMed  Google Scholar 

  • Green LJ, Lin S-Y (2012) DNA damage response and breast cancer: an overview. In: Aft RL (ed) Targeting new pathways and cell death in breast cancer. InTech, Rijeka, pp 97–113

    Google Scholar 

  • Gu F, Ma Y, Zhang Z, Zhao J, Kobayashi H, Zhang L et al (2010) Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep 23(3):671–676

    CAS  PubMed  Google Scholar 

  • Guo L, Liu Y, Bai Y, Sun Y, Xiao F, Guo Y (2010) Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer 46(9):1692–1702

    CAS  PubMed  Google Scholar 

  • Hamano R, Miyata H, Yamasaki M, Kurokawa Y, Hara J, Moon JH et al (2011) Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res 17(9):3029–3038

    CAS  PubMed  Google Scholar 

  • Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB et al (2010) Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PloS One 5(9):e12702

    PubMed Central  PubMed  Google Scholar 

  • He X, He L, Hannon GJ (2007) The guardian’s little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 67(23):11099–11101

    CAS  PubMed  Google Scholar 

  • Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ (2007) High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 6:5

    PubMed Central  PubMed  Google Scholar 

  • Holleman A, Chung I, Olsen RR, Kwak B, Mizokami A, Saijo N et al (2011) miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene 30(43):4386–4398

    CAS  PubMed Central  PubMed  Google Scholar 

  • Hollier BG, Evans K, Mani SA (2009) The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia 14(1):29–43

    PubMed  Google Scholar 

  • Hong L, Han Y, Zhang H, Li M, Gong T, Sun L et al (2010) The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg 251(6):1056–1063

    PubMed  Google Scholar 

  • Hu H, Du L, Nagabayashi G, Seeger RC, Gatti RA (2010a) ATM is down-regulated by N-Myc-regulated microRNA-421. Proc Natl Acad Sci U S A 107(4):1506–1511

    CAS  PubMed Central  PubMed  Google Scholar 

  • Hu W, Chan CS, Wu R, Zhang C, Sun Y, Song JS et al (2010b) Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell 38(5):689–699

    CAS  PubMed Central  PubMed  Google Scholar 

  • Hu H, Li S, Cui X, Lv X, Jiao Y, Yu F et al (2013) The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2). J Biol Chem 288(16):10973–10985

    CAS  PubMed  Google Scholar 

  • Huh JH, Kim TH, Kim K, Song JA, Jung YJ, Jeong JY et al (2013) Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. Br J Cancer 109(2):452–461

    CAS  PubMed  Google Scholar 

  • Hummel R, Watson DI, Smith C, Kist J, Michael MZ, Haier J et al (2011) Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg 15(3):429–438

    PubMed  Google Scholar 

  • Imanaka Y, Tsuchiya S, Sato F, Shimada Y, Shimizu K, Tsujimoto G (2011) MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J Human Genetics 56(4):270–276

    CAS  Google Scholar 

  • Incoronato M, Garofalo M, Urso L, Romano G, Quintavalle C, Zanca C et al (2010) miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res 70(9):3638–3646

    CAS  PubMed  Google Scholar 

  • Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T et al (2009) microRNA-205 regulates HER3 in human breast cancer. Cancer Res 69(6):2195–2200

    CAS  PubMed  Google Scholar 

  • Ivanovska I, Ball AS, Diaz RL, Magnus JF, Kibukawa M, Schelter JM et al (2008) MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol 28(7):2167–2174

    CAS  PubMed Central  PubMed  Google Scholar 

  • Iwagami Y, Eguchi H, Nagano H, Akita H, Hama N, Wada H et al (2013) miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. Br J Cancer 109(2):502–511

    CAS  PubMed  Google Scholar 

  • Jaiswal R, Gong J, Sambasivam S, Combes V, Mathys JM, Davey R et al (2012a) Microparticle-associated nucleic acids mediate trait dominance in cancer. FASEB J 26(1):420–429

    CAS  PubMed  Google Scholar 

  • Jaiswal R, Luk F, Gong J, Mathys JM, Grau GE, Bebawy M (2012b) Microparticle conferred microRNA profiles–implications in the transfer and dominance of cancer traits. Mol Cancer 11:37

    CAS  PubMed Central  PubMed  Google Scholar 

  • Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D et al (2008) Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 8:266

    PubMed Central  PubMed  Google Scholar 

  • Jiao X, Zhao L, Ma M, Bai X, He M, Yan Y et al (2013) MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Breast Cancer Res Treat 139(3):717–730

    CAS  PubMed  Google Scholar 

  • Kalinowski FC, Giles KM, Candy PA, Ali A, Ganda C, Epis MR et al (2012) Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7. PloS One 7(10):e47067

    CAS  PubMed Central  PubMed  Google Scholar 

  • Karaayvaz M, Zhai H, Ju J (2013) miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cell Death Dis 4:e659

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kastl L, Brown I, Schofield AC (2012) miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat 131(2):445–454

    CAS  PubMed  Google Scholar 

  • Kasuga C, Nakahara Y, Ueda S, Hawkins C, Taylor MD, Smith CA et al (2008) Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. Laboratory investigation. J Neurosurg Pediatr 1(4):305–313

    PubMed  Google Scholar 

  • Kim JH, Kim WS, Park C (2012) Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1. Leuk Lymphoma 53(8):1586–1591

    CAS  PubMed  Google Scholar 

  • Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M (2010) MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 70(14):1501–1512

    CAS  PubMed  Google Scholar 

  • Komagata S, Nakajima M, Takagi S, Mohri T, Taniya T, Yokoi T (2009) Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol Pharmacol 76(4):702–709

    CAS  PubMed  Google Scholar 

  • Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D et al (2010) MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 285(23):17869–17879

    CAS  PubMed  Google Scholar 

  • Kong F, Sun C, Wang Z, Han L, Weng D, Lu Y et al (2011) miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. J Huazhong Univ Sci Technol Med Sci 31(4):543–549

    CAS  PubMed  Google Scholar 

  • Kopp F, Oak PS, Wagner E, Roidl A (2012) miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. PloS One 7(11):e50469

    CAS  PubMed Central  PubMed  Google Scholar 

  • Korner C, Keklikoglou I, Bender C, Worner A, Munstermann E, Wiemann S (2013) MicroRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase C epsilon (PKCepsilon). J Biol Chem 288(12):8750–8761

    PubMed  Google Scholar 

  • Kosaka T, Yamaki E, Mogi A, Kuwano H (2011) Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol 2011:165214

    PubMed Central  PubMed  Google Scholar 

  • Kotani A, Ha D, Hsieh J, Rao PK, Schotte D, den Boer ML et al (2009) miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. Blood 114(19):4169–4178

    CAS  PubMed  Google Scholar 

  • Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF et al (2008) Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7(7):2152–2159

    CAS  PubMed  Google Scholar 

  • Kumar M, Lu Z, Takwi AA, Chen W, Callander NS, Ramos KS et al (2011) Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene 30(7):843–853

    CAS  PubMed Central  PubMed  Google Scholar 

  • Lal A, Pan Y, Navarro F, Dykxhoorn DM, Moreau L, Meire E et al (2009) miR-24-mediated downregulation of H2AX suppresses DNA repair in terminally differentiated blood cells. Nat Struct Mol Biol 16(5):492–498

    CAS  PubMed Central  PubMed  Google Scholar 

  • Lam LT, Lu X, Zhang H, Lesniewski R, Rosenberg S, Semizarov D (2010) A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax). Mol Cancer Ther 9(11):2943–2950

    CAS  PubMed  Google Scholar 

  • Lee JW, Choi CH, Choi JJ, Park YA, Kim SJ, Hwang SY et al (2008) Altered MicroRNA expression in cervical carcinomas. Clin Cancer Res 14(9):2535–2542

    CAS  PubMed  Google Scholar 

  • Li T, Li D, Sha J, Sun P, Huang Y (2009a) MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 383(3):280–285

    CAS  PubMed  Google Scholar 

  • Li Y, Li W, Yang Y, Lu Y, He C, Hu G et al (2009b) MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res 1286:13–18

    CAS  PubMed  Google Scholar 

  • Li Y, VandenBoom TG 2nd, Kong D, Wang Z, Ali S, Philip PA et al (2009c) Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69(16):6704–6712

    CAS  PubMed Central  PubMed  Google Scholar 

  • Li Y, Zhu X, Gu J, Dong D, Yao J, Lin C et al (2010a) Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. Cancer Sci 101(4):948–954

    CAS  PubMed  Google Scholar 

  • Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L et al (2010b) MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol 119(1):125–130

    CAS  PubMed  Google Scholar 

  • Li J, Chen Y, Zhao J, Kong F, Zhang Y (2011a) miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. Cancer Lett 304(1):52–59

    CAS  PubMed  Google Scholar 

  • Li J, Zhang Y, Zhao J, Kong F, Chen Y (2011b) Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells. Mol Cell Biochem 357(1–2):31–38

    CAS  PubMed  Google Scholar 

  • Li H, Hui L, Xu W (2012a) miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. Acta Biochim Biophys Sin 44(3):269–277

    CAS  PubMed  Google Scholar 

  • Li XJ, Ji MH, Zhong SL, Zha QB, Xu JJ, Zhao JH et al (2012b) MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1. Arch Med Res 43(7):514–521

    CAS  PubMed  Google Scholar 

  • Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K et al (2010) Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharm 79(6):817–824

    CAS  PubMed Central  PubMed  Google Scholar 

  • Liang Z, Li Y, Huang K, Wagar N, Shim H (2011) Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res 28(12):3091–3100

    CAS  PubMed Central  PubMed  Google Scholar 

  • Lima RT, Busacca S, Almeida GM, Gaudino G, Fennell DA, Vasconcelos MH (2011) MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer 47(2):163–174

    CAS  PubMed  Google Scholar 

  • Liu L, Chen R, Huang S, Wu Y, Li G, Zhang B et al (2012a) miR-153 sensitized the K562 cells to As2O3-induced apoptosis. Med Oncol 29(1):243–247

    CAS  PubMed  Google Scholar 

  • Liu L, Wang S, Chen R, Wu Y, Zhang B, Huang S et al (2012b) Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562. Biochem Biophys Res Commun 425(2):368–373

    CAS  PubMed  Google Scholar 

  • Liu N, Zhou C, Zhao J, Chen Y (2012c) Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera. Cancer Invest 30(8):577–582

    CAS  PubMed  Google Scholar 

  • Liu S, Tetzlaff MT, Cui R, Xu X (2012d) miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1. Am J Pathol 181(5):1823–1835

    CAS  PubMed  Google Scholar 

  • Liu Y, Xing R, Zhang X, Dong W, Zhang J, Yan Z et al (2013a) miR-375 targets the p53 gene to regulate cellular response to ionizing radiation and etoposide in gastric cancer cells. DNA Repair 12(9):741–750

    CAS  PubMed  Google Scholar 

  • Liu Z, Liu H, Desai S, Schmitt DC, Zhou M, Khong HT et al (2013b) miR-125b functions as a key mediator for snail-induced stem cell propagation and chemoresistance. J Biol Chem 288(6):4334–4345

    CAS  PubMed  Google Scholar 

  • Liu ZL, Wang H, Liu J, Wang ZX (2013c) MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem 372(1–2):35–45

    CAS  PubMed  Google Scholar 

  • Lopes-Rodrigues V, Seca H, Sousa D, Sousa E, Lima RT, Vasconcelos MH (2013) The network of P-glycoprotein and microRNAs interactions. Int J Cancer. doi:10.1002/ijc.28500. [Epub ahead of print]

  • Lv K, Liu L, Wang L, Yu J, Liu X, Cheng Y et al (2012) Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells. PloS One 7(7):e40008

    CAS  PubMed Central  PubMed  Google Scholar 

  • Lwin T, Lin J, Choi YS, Zhang X, Moscinski LC, Wright KL et al (2010) Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a. Blood 116(24):5228–5236

    CAS  PubMed  Google Scholar 

  • Ma K, He Y, Zhang H, Fei Q, Niu D, Wang D et al (2012) DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J Biol Chem 287(8):5639–5649

    CAS  PubMed  Google Scholar 

  • Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704–715

    CAS  PubMed Central  PubMed  Google Scholar 

  • Mencia N, Selga E, Noe V, Ciudad CJ (2011) Underexpression of miR-224 in methotrexate resistant human colon cancer cells. Biochem Pharm 82(11):1572–1582

    CAS  PubMed  Google Scholar 

  • Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT et al (2006) Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130(7):2113–2129

    CAS  PubMed  Google Scholar 

  • Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL et al (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283(44):29897–29903

    CAS  PubMed  Google Scholar 

  • Mishra PJ, Humeniuk R, Longo-Sorbello GS, Banerjee D, Bertino JR (2007) A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci U S A 104(33):13513–13518

    CAS  PubMed Central  PubMed  Google Scholar 

  • Mishra PJ, Banerjee D, Bertino JR (2008) MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: introducing microRNA pharmacogenomics. Cell Cycle 7(7):853–858

    CAS  PubMed  Google Scholar 

  • Mishra PJ, Song B, Wang Y, Humeniuk R, Banerjee D, Merlino G et al (2009) MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. PloS One 4(12):e8445

    PubMed Central  PubMed  Google Scholar 

  • Mitamura T, Watari H, Wang L, Kanno H, Hassan MK, Miyazaki M et al (2013) Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis 2:e40

    CAS  PubMed Central  PubMed  Google Scholar 

  • Mohri T, Nakajima M, Fukami T, Takamiya M, Aoki Y, Yokoi T (2010) Human CYP2E1 is regulated by miR-378. Biochem Pharmacol 79(7):1045–1052

    CAS  PubMed  Google Scholar 

  • Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ et al (2011) miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 41(2):210–220

    CAS  PubMed Central  PubMed  Google Scholar 

  • Muralidharan-Chari V, Clancy JW, Sedgwick A, D’Souza-Schorey C (2010) Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci 123(Pt 10):1603–1611

    CAS  PubMed  Google Scholar 

  • Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD et al (1997) Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 57(14):3026–3031

    CAS  PubMed  Google Scholar 

  • Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG et al (2010) A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol 24(2):447–463

    CAS  PubMed  Google Scholar 

  • Nakatani F, Ferracin M, Manara MC, Ventura S, Del Monaco V, Ferrari S et al (2012) miR-34a predicts survival of Ewing’s sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol 226(5):796–805

    CAS  PubMed  Google Scholar 

  • Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S et al (2008) Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 283(48):33394–33405

    CAS  PubMed  Google Scholar 

  • Nishida N, Yamashita S, Mimori K, Sudo T, Tanaka F, Shibata K et al (2012) MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann Surg Oncol 19(9):3065–3071

    PubMed  Google Scholar 

  • Pan YZ, Gao W, Yu AM (2009a) MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 37(10):2112–2117

    CAS  PubMed  Google Scholar 

  • Pan YZ, Morris ME, Yu AM (2009b) MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 75(6):1374–1379

    CAS  PubMed  Google Scholar 

  • Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I et al (2008) E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 13(3):272–286

    CAS  PubMed  Google Scholar 

  • Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O (2010) Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer (Journal International du Cancer) 127(8):1785–1794

    CAS  Google Scholar 

  • Pothof J, Verkaik NS, van IJcken W, Wiemer EA, Ta VT, van der Horst GT et al (2009) MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response. EMBO J 28(14):2090–2099

    CAS  PubMed  Google Scholar 

  • Pu J, Bai D, Yang X, Lu X, Xu L, Lu J (2012) Adrenaline promotes cell proliferation and increases chemoresistance in colon cancer HT29 cells through induction of miR-155. Biochem Biophys Res Commun 428(2):210–215

    CAS  PubMed  Google Scholar 

  • Puhr M, Hoefer J, Schafer G, Erb HH, Oh SJ, Klocker H et al (2012) Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol 181(6):2188–2201

    CAS  PubMed  Google Scholar 

  • Qian X, Yu J, Yin Y, He J, Wang L, Li Q et al (2013) MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle 12(9):1385–1394

    CAS  PubMed  Google Scholar 

  • Qu J, Zhao L, Zhang P, Wang J, Xu N, Mi W et al (2013) MicroRNA-195 chemosensitizes colon cancer cells to the chemotherapeutic drug doxorubicin by targeting the first binding site of BCL2L2 mRNA. J Cell Physiol. doi:10.1002/jcp.24366. [Epub ahead of print]

  • Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C et al (2011) MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 30(9):1082–1097

    CAS  PubMed Central  PubMed  Google Scholar 

  • Rao E, Jiang C, Ji M, Huang X, Iqbal J, Lenz G et al (2012) The miRNA-17 approximately 92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia 26(5):1064–1072

    CAS  PubMed  Google Scholar 

  • Razumilava N, Bronk SF, Smoot RL, Fingas CD, Werneburg NW, Roberts LR et al (2012) miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology 55(2):465–475

    CAS  PubMed Central  PubMed  Google Scholar 

  • Rebucci M, Michiels C (2013) Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol 85(9):1219–1226

    CAS  PubMed  Google Scholar 

  • Rokhlin OW, Scheinker VS, Taghiyev AF, Bumcrot D, Glover RA, Cohen MB (2008) MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther 7(8):1288–1296

    CAS  PubMed  Google Scholar 

  • Romano G, Acunzo M, Garofalo M, Di Leva G, Cascione L, Zanca C et al (2012) MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. Proc Natl Acad Sci U S A 109(41):16570–16575

    CAS  PubMed Central  PubMed  Google Scholar 

  • Rossi L, Bonmassar E, Faraoni I (2007) Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro. Pharmacol Res 56(3):248–253

    CAS  PubMed  Google Scholar 

  • Ru P, Steele R, Hsueh EC, Ray RB (2011) Anti-miR-203 upregulates SOCS3 expression in breast cancer cells and enhances cisplatin chemosensitivity. Genes Cancer 2(7):720–727

    CAS  PubMed Central  PubMed  Google Scholar 

  • Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, Naerdemann W et al (2005) Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther 4(10):1595–1604

    CAS  PubMed  Google Scholar 

  • Seca H, Lima RT, Lopes-Rodrigues V, Guimaraes JE, Almeida GM, Vasconcelos MH (2013) Targeting miR-21 induces autophagy and chemosensitivity of leukemia cells. Curr Drug Targets 14(10):1135–1143

    CAS  PubMed  Google Scholar 

  • Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, Horikawa I et al (2009) MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A 106(29):12085–12090

    CAS  PubMed Central  PubMed  Google Scholar 

  • Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3(75):75ra26

    PubMed Central  PubMed  Google Scholar 

  • Shen Y, Wang P, Li Y, Ye F, Wang F, Wan X et al (2013) miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer. Br J Cancer 109(1):92–99

    CAS  PubMed Central  PubMed  Google Scholar 

  • Sheng J, Luo W, Yu F, Gao N, Hu B (2013) MicroRNA-376a sensitizes cells following DNA damage by downregulating MEPE expression. Cancer Biother Radiopharm 28(7):523–529

    CAS  PubMed  Google Scholar 

  • Shi GH, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL et al (2010) Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin 31(7):867–873

    CAS  PubMed  Google Scholar 

  • Shi W, Gerster K, Alajez NM, Tsang J, Waldron L, Pintilie M et al (2011) MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res 71(8):2926–2937

    CAS  PubMed  Google Scholar 

  • Shi L, Zhang S, Feng K, Wu F, Wan Y, Wang Z et al (2012a) MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol 40(1):119–129

    PubMed  Google Scholar 

  • Shi M, Du L, Liu D, Qian L, Hu M, Yu M et al (2012b) Glucocorticoid regulation of a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy resistance of cervical cancer cells. J Pathol 228(2):148–157

    CAS  PubMed  Google Scholar 

  • Shi TY, Cheng X, Yu KD, Sun MH, Shao ZM, Wang MY et al (2013) Functional variants in TNFAIP8 associated with cervical cancer susceptibility and clinical outcomes. Carcinogenesis 34(4):770–778

    CAS  PubMed  Google Scholar 

  • Shimizu S, Takehara T, Hikita H, Kodama T, Miyagi T, Hosui A et al (2010) The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol 52(5):698–704

    CAS  PubMed  Google Scholar 

  • Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI et al (2009a) Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 28(46):4065–4074

    CAS  PubMed Central  PubMed  Google Scholar 

  • Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ et al (2009b) The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest 119(12):3626–3636

    CAS  PubMed Central  PubMed  Google Scholar 

  • Song B, Wang Y, Titmus MA, Botchkina G, Formentini A, Kornmann M et al (2010) Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer 9:96

    CAS  PubMed Central  PubMed  Google Scholar 

  • Srivastava N, Manvati S, Srivastava A, Pal R, Kalaiarasan P, Chattopadhyay S et al (2011) miR-24-2 controls H2AFX expression regardless of gene copy number alteration and induces apoptosis by targeting antiapoptotic gene BCL-2: a potential for therapeutic intervention. Breast Cancer Res 13(2):R39

    PubMed Central  PubMed  Google Scholar 

  • Stegmeier F, Warmuth M, Sellers WR, Dorsch M (2010) Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther 87(5):543–552

    CAS  PubMed  Google Scholar 

  • Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y et al (2009) MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 69(3):1135–1142

    CAS  PubMed  Google Scholar 

  • Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M et al (2012) MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 31(4):432–445

    CAS  PubMed  Google Scholar 

  • Takagi S, Nakajima M, Mohri T, Yokoi T (2008) Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem 283(15):9674–9680

    CAS  PubMed  Google Scholar 

  • Tao J, Lu Q, Wu D, Li P, Xu B, Qing W et al (2011) microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells. Oncol Rep 25(6):1721–1729

    CAS  PubMed  Google Scholar 

  • Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7(2):131–142

    CAS  PubMed  Google Scholar 

  • Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871–890

    CAS  PubMed  Google Scholar 

  • To KK, Robey RW, Knutsen T, Zhan Z, Ried T, Bates SE (2009) Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. Mol Cancer Ther 8(10):2959–2968

    CAS  PubMed Central  PubMed  Google Scholar 

  • Tomimaru Y, Eguchi H, Nagano H, Wada H, Tomokuni A, Kobayashi S et al (2010) MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 103(10):1617–1626

    CAS  PubMed Central  PubMed  Google Scholar 

  • Toscano-Garibay JD, Aquino-Jarquin G (2012) Regulation exerted by miRNAs in the promoter and UTR sequences: MDR1/P-gp expression as a particular case. DNA Cell Biol 31(8):1358–1364

    CAS  PubMed  Google Scholar 

  • Tryndyak VP, Beland FA, Pogribny IP (2010) E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 126(11):2575–2583

    CAS  PubMed  Google Scholar 

  • Tsang WP, Kwok TT (2008) Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 13(10):1215–1222

    CAS  PubMed  Google Scholar 

  • Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T (2006) MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res 66(18):9090–9098

    CAS  PubMed  Google Scholar 

  • Ujifuku K, Mitsutake N, Takakura S, Matsuse M, Saenko V, Suzuki K et al (2010) miR-195, miR-455-3p and miR-10aare implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett 296(2):241–248

    CAS  PubMed  Google Scholar 

  • Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M et al (2010) MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A 107(49):21098–21103

    CAS  PubMed Central  PubMed  Google Scholar 

  • van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E et al (2012) miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 32(36):4284–4293

    PubMed  Google Scholar 

  • Vazquez A, Bond EE, Levine AJ, Bond GL (2008) The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 7(12):979–987

    CAS  PubMed  Google Scholar 

  • Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, Borovski T et al (2010) Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12(5):468–476

    CAS  PubMed  Google Scholar 

  • Vinall RL, Ripoll AZ, Wang S, Pan CX, deVere White RW (2012) MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int J Cancer 130(11):2526–2538

    CAS  PubMed  Google Scholar 

  • Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F et al (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103(7):2257–2261

    CAS  PubMed Central  PubMed  Google Scholar 

  • Wang Q, Zhong M, Liu W, Li J, Huang J, Zheng L (2011a) Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 37(7):427–434

    CAS  PubMed  Google Scholar 

  • Wang X, Li C, Ju S, Wang Y, Wang H, Zhong R (2011b) Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation. Leuk Lymphoma 52(10):1991–1998

    CAS  PubMed  Google Scholar 

  • Wang Y, Huang JW, Li M, Cavenee WK, Mitchell PS, Zhou X et al (2011c) MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. Mol Cancer Res 9(8):1100–1111

    CAS  PubMed Central  PubMed  Google Scholar 

  • Wang ZX, Lu BB, Wang H, Cheng ZX, Yin YM (2011d) MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Arch Med Res 42(4):281–290

    CAS  PubMed  Google Scholar 

  • Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z et al (2012a) Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PloS One 7(4):e34210

    CAS  PubMed Central  PubMed  Google Scholar 

  • Wang Y, Huang JW, Calses P, Kemp CJ, Taniguchi T (2012b) MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. Cancer Res 72(16):4037–4046

    CAS  PubMed Central  PubMed  Google Scholar 

  • Wang YS, Wang YH, Xia HP, Zhou SW, Schmid-Bindert G, Zhou CC (2012c) MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. Asian Pac J Cancer Prev 13(1):255–260

    PubMed  Google Scholar 

  • Wang F, Li T, Zhang B, Li H, Wu Q, Yang L et al (2013a) MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 434(3):688–694

    CAS  PubMed  Google Scholar 

  • Wang F, Liu M, Li X, Tang H (2013b) MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett 587(5):488–495

    CAS  PubMed  Google Scholar 

  • Ward A, Balwierz A, Zhang JD, Kublbeck M, Pawitan Y, Hielscher T et al (2013) Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene 32(9):1173–1182

    CAS  PubMed  Google Scholar 

  • Weeraratne SD, Amani V, Neiss A, Teider N, Scott DK, Pomeroy SL et al (2011) miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol 13(2):165–175

    CAS  PubMed Central  PubMed  Google Scholar 

  • Wilting RH, Dannenberg JH (2012) Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist Update 15(1–2):21–38

    CAS  Google Scholar 

  • Wong MY, Yu Y, Walsh WR, Yang JL (2011) microRNA-34 family and treatment of cancers with mutant or wild-type p53 (Review). Int J Oncol 38(5):1189–1195

    CAS  PubMed  Google Scholar 

  • Wu Y, Xiao Y, Ding X, Zhuo Y, Ren P, Zhou C et al (2011) A miR-200b/200c/429-binding site polymorphism in the 3′ untranslated region of the AP-2alpha gene is associated with cisplatin resistance. PloS One 6(12):e29043

    CAS  PubMed Central  PubMed  Google Scholar 

  • Wu CW, Dong YJ, Liang QY, He XQ, Ng SS, Chan FK et al (2013a) MicroRNA-18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer. PloS One 8(2):e57036

    CAS  PubMed Central  PubMed  Google Scholar 

  • Wu H, Huang M, Lu M, Zhu W, Shu Y, Cao P et al (2013b) Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel. Cancer Chemother Pharmacol 71(5):1159–1171

    CAS  PubMed  Google Scholar 

  • Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S et al (2008) miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 123(2):372–379

    CAS  PubMed  Google Scholar 

  • Xia H, Ooi LL, Hui KM (2013) MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology 58(2):629–641

    CAS  PubMed  Google Scholar 

  • Xiang Q, Tang H, Yu J, Yin J, Yang X, Lei X (2013a) MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2. Pharmazie 68(4):274–281

    CAS  PubMed  Google Scholar 

  • Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G et al (2013b) MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene. doi:10.1038/onc.2012.575. [Epub ahead of print]

  • Xie Y, Tobin LA, Camps J, Wangsa D, Yang J, Rao M et al (2013) MicroRNA-24 regulates XIAP to reduce the apoptosis threshold in cancer cells. Oncogene 32(19):2442–2451

    CAS  PubMed Central  PubMed  Google Scholar 

  • Xu B, Niu X, Zhang X, Tao J, Wu D, Wang Z et al (2011a) miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem 350(1–2):207–213

    CAS  PubMed  Google Scholar 

  • Xu Y, Xia F, Ma L, Shan J, Shen J, Yang Z et al (2011b) MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett 310(2):160–169

    CAS  PubMed  Google Scholar 

  • Xu K, Liang X, Shen K, Cui D, Zheng Y, Xu J et al (2012a) miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2. Biochem J 446(2):291–300

    CAS  PubMed  Google Scholar 

  • Xu K, Liang X, Shen K, Sun L, Cui D, Zhao Y et al (2012b) MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17. Exp Cell Res 318(17):2168–2177

    CAS  PubMed  Google Scholar 

  • Xu N, Shen C, Luo Y, Xia L, Xue F, Xia Q et al (2012c) Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochem Biophys Res Commun 425(2):468–472

    CAS  PubMed  Google Scholar 

  • Xu N, Zhang J, Shen C, Luo Y, Xia L, Xue F et al (2012d) Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem Biophys Res Commun 423(4):826–831

    CAS  PubMed  Google Scholar 

  • Xu XT, Xu Q, Tong JL, Zhu MM, Nie F, Chen X et al (2012e) MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer. Br J Cancer 106(7):1320–1330

    CAS  PubMed Central  PubMed  Google Scholar 

  • Xu K, Liang X, Cui D, Wu Y, Shi W, Liu J (2013) miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. Mol Carcinog 52(1):70–78

    CAS  PubMed  Google Scholar 

  • Yamamoto Y, Yoshioka Y, Minoura K, Takahashi RU, Takeshita F, Taya T et al (2011) An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. Mol Cancer 10:135

    CAS  PubMed Central  PubMed  Google Scholar 

  • Yang H, Kong W, He L, Zhao JJ, O’Donnell JD, Wang J et al (2008a) MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68(2):425–433

    CAS  PubMed  Google Scholar 

  • Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K et al (2008b) MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 68(24):10307–10314

    CAS  PubMed Central  PubMed  Google Scholar 

  • Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY, Yang WH et al (2010) Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 12(10):982–992

    PubMed  Google Scholar 

  • Yang A, Ma J, Wu M, Qin W, Zhao B, Shi Y et al (2012a) Aberrant microRNA-182 expression is associated with glucocorticoid resistance in lymphoblastic malignancies. Leuk Lymphoma 53(12):2465–2473

    CAS  PubMed  Google Scholar 

  • Yang C, Cai J, Wang Q, Tang H, Cao J, Wu L et al (2012b) Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1. Gynecol Oncol 124(2):325–334

    CAS  PubMed  Google Scholar 

  • Yang L, Li N, Wang H, Jia X, Wang X, Luo J (2012c) Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol Rep 28(2):592–600

    CAS  PubMed  Google Scholar 

  • Yang MY, Lin PM, Liu YC, Hsiao HH, Yang WC, Hsu JF et al (2012d) Induction of cellular senescence by doxorubicin is associated with upregulated miR-375 and induction of autophagy in K562 cells. PloS One 7(5):e37205

    CAS  PubMed Central  PubMed  Google Scholar 

  • Yang X, Yin J, Yu J, Xiang Q, Liu Y, Tang S et al (2012e) miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w. Oncol Rep 27(1):250–257

    CAS  PubMed  Google Scholar 

  • Yang YP, Chien Y, Chiou GY, Cherng JY, Wang ML, Lo WL et al (2012f) Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials 33(5):1462–1476

    CAS  PubMed  Google Scholar 

  • Ye G, Fu G, Cui S, Zhao S, Bernaudo S, Bai Y et al (2011) MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci 124(Pt 3):359–368

    CAS  PubMed  Google Scholar 

  • Yu ZW, Zhong LP, Ji T, Zhang P, Chen WT, Zhang CP (2010) MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 46(4):317–322

    CAS  PubMed  Google Scholar 

  • Yu Y, Cao L, Yang L, Kang R, Lotze M, Tang D (2012a) microRNA 30A promotes autophagy in response to cancer therapy. Autophagy 8(5):853–855

    CAS  PubMed  Google Scholar 

  • Yu Y, Yang L, Zhao M, Zhu S, Kang R, Vernon P et al (2012b) Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells. Leukemia 26(8):1752–1760

    CAS  PubMed  Google Scholar 

  • Zang YS, Zhong YF, Fang Z, Li B, An J (2012) MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression. Cancer Gene Ther 19(11):773–778

    CAS  PubMed  Google Scholar 

  • Zannis-Hadjopoulos M, Yahyaoui W, Callejo M (2008) 14-3-3 cruciform-binding proteins as regulators of eukaryotic DNA replication. Trends Biochem Sci 33(1):44–50

    CAS  PubMed  Google Scholar 

  • Zhang W, Dolan ME (2010) The emerging role of microRNAs in drug responses. Curr Opin Mol Ther 12(6):695–702

    CAS  PubMed Central  PubMed  Google Scholar 

  • Zhang H, Li M, Han Y, Hong L, Gong T, Sun L et al (2010a) Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 55(9):2545–2551

    CAS  PubMed  Google Scholar 

  • Zhang J, Zhang T, Ti X, Shi J, Wu C, Ren X et al (2010b) Curcumin promotes apoptosis in A549/DDP multidrug-resistant human lung adenocarcinoma cells through an miRNA signaling pathway. Biochem Biophys Res Commun 399(1):1–6

    CAS  PubMed  Google Scholar 

  • Zhang P, Wang H, Rowe PS, Hu B, Wang Y (2010c) MEPE/OF45 as a new target for sensitizing human tumour cells to DNA damage inducers. Br J Cancer 102(5):862–866

    CAS  PubMed Central  PubMed  Google Scholar 

  • Zhang H, Luo XQ, Feng DD, Zhang XJ, Wu J, Zheng YS et al (2011a) Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia. Mol Cancer 10:108

    CAS  PubMed Central  PubMed  Google Scholar 

  • Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M et al (2011b) A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol 22(1):104–109

    CAS  PubMed  Google Scholar 

  • Zhang X, Zhu J, Xing R, Tie Y, Fu H, Zheng X et al (2012) miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. Lung Cancer 77(3):488–494

    PubMed  Google Scholar 

  • Zhang JX, Qian D, Wang FW, Liao DZ, Wei JH, Tong ZT et al (2013) MicroRNA-29c enhances the sensitivities of human nasopharyngeal carcinoma to cisplatin-based chemotherapy and radiotherapy. Cancer Lett 329(1):91–98

    CAS  PubMed  Google Scholar 

  • Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X et al (2008) MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 283(45):31079–31086

    CAS  PubMed  Google Scholar 

  • Zhao X, Yang L, Hu J, Ruan J (2010) miR-138 might reverse multidrug resistance of leukemia cells. Leuk Res 34(8):1078–1082

    CAS  PubMed  Google Scholar 

  • Zhao X, Yang L, Hu J (2011a) Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 30:55

    CAS  PubMed  Google Scholar 

  • Zhao Y, Deng C, Lu W, Xiao J, Ma D, Guo M et al (2011b) let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor alpha signaling in breast cancer. Mol Med 17(11–12):1233–1241

    CAS  PubMed Central  PubMed  Google Scholar 

  • Zhong M, Ma X, Sun C, Chen L (2010) MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer. Chem Biol Interact 184(3):431–438

    CAS  PubMed  Google Scholar 

  • Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y et al (2010) MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 285(28):21496–21507

    CAS  PubMed  Google Scholar 

  • Zhou L, Qiu T, Xu J, Wang T, Wang J, Zhou X et al (2013) miR-135a/b modulate cisplatin resistance of human lung cancer cell line by targeting MCL1. Pathol Oncol Res 19(4):677–683

    CAS  PubMed  Google Scholar 

  • Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG et al (2008) Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 76(5):582–588

    CAS  PubMed Central  PubMed  Google Scholar 

  • Zhu H, Wu H, Liu X, Li B, Chen Y, Ren X et al (2009) Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells. Autophagy 5(6):816–823

    CAS  PubMed  Google Scholar 

  • Zhu W, Shan X, Wang T, Shu Y, Liu P (2010) miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 127(11):2520–2529

    CAS  PubMed  Google Scholar 

  • Zhu Y, Yu F, Jiao Y, Feng J, Tang W, Yao H et al (2011) Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res 17(22):7105–7115

    CAS  PubMed  Google Scholar 

  • Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J et al (2012a) miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 69(3):723–731

    CAS  PubMed  Google Scholar 

  • Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang B et al (2012b) miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 29(1):384–391

    CAS  PubMed  Google Scholar 

  • Zhu X, Li H, Long L, Hui L, Chen H, Wang X et al (2012c) miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim Biophys Sin 44(6):519–526

    CAS  PubMed  Google Scholar 

  • Ziliak D, Gamazon ER, Lacroix B, Kyung Im H, Wen Y, Huang RS (2012) Genetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility. Mol Cancer Ther 11(9):2054–2061

    CAS  PubMed Central  PubMed  Google Scholar 

  • Zou Z, Wu L, Ding H, Wang Y, Zhang Y, Chen X et al (2012) MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. J Biol Chem 287(6):4148–4156

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Drug Resistance Group, Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), Rua Doutor Roberto Frias s/n, 4200, Porto, Portugal

    Hugo Seca, Raquel T. Lima & M. Helena Vasconcelos

  2. Laboratório de Microbiologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira n.º 228, 4050-313, Porto, Portugal

    Hugo Seca & M. Helena Vasconcelos

  3. Centro de Química Medicinal da Universidade do Porto (CEQUIMED-UP), Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira n.º 228, 4050-313, Porto, Portugal

    Raquel T. Lima

Authors
  1. Hugo Seca
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raquel T. Lima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Helena Vasconcelos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Helena Vasconcelos .

Editor information

Editors and Affiliations

  1. Dept. of Molec. Genetics, Fac. of Biological Sciences, Tarbiat Modares University, Tehran, Iran

    Sadegh Babashah

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Seca, H., Lima, R.T., Vasconcelos, M.H. (2014). MicroRNAs in Cancer Drug Resistance and Drug Sensitivity. In: Babashah, S. (eds) MicroRNAs: Key Regulators of Oncogenesis. Springer, Cham. https://doi.org/10.1007/978-3-319-03725-7_11

Download citation

Publish with us

Policies and ethics

Search

Navigation